Daiichi Sankyo’s AML Drug Among Nine CHMP Hopefuls

EMA Panel Poised To Adopt Opinion On EU-Wide Approval Of New Drugs

Will regulators in the EU follow their US counterparts in requiring more efficacy data for Daiichi Sankyo’s acute myeloid leukemia drug quizartinib, which is already approved in Japan?

Leukemia
AML Drug Quizartinib Is Up For CHMP Opinion • Source: Shutterstock

Sponsors of nine new drugs, including Daiichi Sankyo for its anticancer medicine, quizartinib, Janssen for its anti-depressant, esketamine, and AbbVie for its rheumatoid arthritis treatment, upadacitinib, are set to learn whether their products are on track to secure a pan-EU approval.

Marketing authorization applications (MAAs) for the products are up for an opinion this week by the European Medicines Agency’s drug...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet